The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 years, more untreated controls died than those treated with IV edaravone. Treatment with ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study ...
Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to ...
There is a much greater need for new therapies for progressive forms of MS than for relapsing forms of the disease. While relapsing forms are characterised by sudden attacks associated with ...